Guardant Health (FRA:5GH) Research & Development : €330.8 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Guardant Health Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Guardant Health's Research & Development for the three months ended in Mar. 2024 was €77.1 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was €330.8 Mil.

Guardant Health Research & Development Historical Data

The historical data trend for Guardant Health's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guardant Health Research & Development Chart

Guardant Health Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Research & Development

Get a 7-Day Free Trial

77.66

123.19

232.95

352.87

336.72

Guardant Health Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Research & Development	Get a 7-Day Free Trial															86.98	83.40	87.94	82.40	77.10

Guardant Health Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €330.8 Mil.

Guardant Health (FRA:5GH) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Guardant Health Research & Development Related Terms

Thank you for viewing the detailed overview of Guardant Health's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Guardant Health (FRA:5GH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Guardant Health Inc (FRA:5GH) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

GH:USA

Address

3100 Hanover Street, Palo Alto, CA, USA, 94304

Website

https://www.guardanthealth.com

Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Guardant Health (FRA:5GH) Headlines

No Headlines